A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04357756
• Other study ID #: YH001002
• Status: Completed
• Phase: Phase 1
• Start date: April 21, 2020
• Est. completion date: October 19, 2022

Study information

• Verified date: September 2023
• Source: Eucure (Beijing) Biopharma Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors.

Description:

This trial will have a run-in phase to explore the safety and tolerability of YH001 as a single agent for 21 days as DLT observation period then followed by a combination phase to further explore the safety and tolerability of YH001 combined with Toripalimab (anti-PD-1 antibody) for each dose level during dose escalation.

The dose escalation will follow the traditional "3 + 3" dose escalation scheme. These subjects will be treated with YH001 and Toripalimab. YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G. Toripalimab will be administered by IV (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle. A single subject will be enrolled at Dose A as starting dose of YH001, and subsequent cohort will be expanded to include 3-6 subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: October 19, 2022
• Est. primary completion date: October 19, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, aged = 18 years

• Have advanced histologically or cytologically confirmed solid tumor

• Have progressed on after treatment with standard therapies or intolerant of standard care

• At least 1 unidimensional measurable target lesion per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

• Have life expectancy of at least 12 weeks based on investigator's judgement

Exclusion Criteria:

• Treated with any investigational drug within 4 weeks prior to the fist dose of study drug

• Received any anticancer therapy less than 28 days prior to the first administration of study drug or within 5 half-lives of the therapy agent, whichever is shorter. Prior palliative radiotherapy to bone metastases = 2 weeks prior to the first dose of YH001 is acceptable

• Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded

• Subjects with prior PD-1/L1 treatment intolerate to PD-1/L1 therapy should be excluded

• Subjects with a history of = Grade 3 immune-related adverse events (AEs) resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy

• Subjects with a history of = Grade 2 pneumonitis resulted from previous immunotherapy or with a SpO2 by pulse oximetry < 92% at the screening

• Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial. Inhaled or topical steroids, and adrenal replacement steroid doses = 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Ophthalmologic, nasal and intra-articular injections of steroids are allowed

• Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. Exceptions are subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy

• Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. But subjects with asymptomatic CNS metastases might be eligible if they have no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and the first dose of YH001 and are currently not receiving corticosteroids

• QTc > 450 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome

• Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to = Grade 1 per CTCAE v5.0, except alopecia, < Grade 2 sensory neuropathy

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• YH001
YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
• Toripalimab
Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.

Locations

Country	Name	City	State
Australia	Blacktown Hospital, Blacktown Cancer and Haematology Centre	Blacktown	New South Wales
Australia	Peninsula & South Eastern Haematology and Oncology Group	Frankston	Victoria
Australia	St George Private Hospital	Kogarah	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Eucure (Beijing) Biopharma Co., Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events and serious adverse events	The safety profile of YH001 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	From screening up to 1 year
Primary	Maximum tolerated dose (MTD)	MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle	During Cycle 1 (each cycle is 21 days)
Primary	Dose-limiting toxicities (DLT)	DLT is defined as a toxicity (adverse event at least possibly related to YH001) occurring during the DLT observation period (the initial 21 days) both in run-in phase of YH001 as single agent and in combination phase of YH001 in combination with Toripalimab	During Cycle 1 (each cycle is 21 days)
Secondary	Area under the serum concentration versus time curve within one dosing interval (AUCtau)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Steady state AUC	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Maximum serum concentration (Cmax)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Trough concentration before the next dose is administered (Ctrough)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Time to reach maximum serum concentration (Tmax)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Clearance (CL)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Volume of distribution (Vd)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Terminal half-life (T1/2)	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Dose proportionality	To determine the PK profile of YH001 alone and in combination with Toripalimab	Up to 1 year
Secondary	Incidence of anti-drug antibodies (ADAs)	To assess the immunogenicity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Incidence of neutralizing antibodies (NAbs)	To assess the immunogenicity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Objective response rate (ORR)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Duration of response (DOR)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Time to response (TTR)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Progression free survival (PFS)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Overall survival (OS)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Disease control rate (DCR)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year
Secondary	Duration of disease control (DDC)	To assess the preliminary antitumor activity of YH001 in combination with Toripalimab	Up to 1 year